Finance

Beta
Lists
AMGN:NASDAQ
Amgen Inc
$351.40
+1.26%
(+4.38) 1D
$346.17
-1.49% (-5.22)
After hours
Closed: Jun 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMGN...
Open
$348.00
High
$354.42
Low
$346.00
Mkt. cap
189.65B
Avg. vol.
2.91M
Volume
0.00
Dividend
2.87%
Quarterly dividend
$2.52
Ex-dividend date
May 15, 2026
P/E ratio
24.43
52-wk high
$391.29
52-wk low
$269.77
EPS
$14.38
Beta
0.42
Shares outstanding
539.71M
No. of employees
32K
Open
$348.00
High
$354.42
Low
$346.00
Mkt. cap
189.65B
Avg. vol.
2.91M
Volume
0.00
Dividend
2.87%
Quarterly dividend
$2.52
Ex-dividend date
May 15, 2026
P/E ratio
24.43
52-wk high
$391.29
52-wk low
$269.77
EPS
$14.38
Beta
0.42
Shares outstanding
539.71M
No. of employees
32K
News stories
From sources across the web
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31.5K
FoundedApr 8, 1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteamgen.com
Analyst Ratings
Based on 24 analysts giving stock ratings to AMGN in the past 3 months
Buy
Buy
10
Hold
13
Sell
1
12 month forecast
Based on 24 Wall Street analysts offering 12 month price targets for AMGN in the last 3 months.
Highest
Current $351.40
$427.00 (+21.52%)
Average
$357.38 (+1.70%)
Lowest
$300.00 (-14.63%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Salim Syed
Mizuho Securities
Hold
Maintained
$303.00
-13.8%
06/21/2026
Luca Issi
RBC Capital
Buy
Reiterated
$370.00
+5.3%
06/18/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$427.00
+21.5%
06/12/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$340.00
-3.2%
06/10/2026
Courtney Breen
Bernstein
Hold
Maintained
-
-
06/09/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$389.00
+10.7%
06/05/2026
Yaron Werber
TD Cowen
Buy
Maintained
$326.31
-7.1%
05/18/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Upgraded
$375.00
+6.7%
05/07/2026
Hans Engel
Erste Group
Hold
Downgraded
-
-
05/05/2026
Emily Field
Barclays
Hold
Maintained
$350.00
-0.4%
05/05/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$400.00
+13.8%
05/04/2026
Vamil Divan
Guggenheim
Hold
Maintained
$340.00
-3.2%
05/03/2026
Unknown Analyst
Raymond James
Hold
Reiterated
-
-
05/01/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
05/01/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
05/01/2026
Carter Gould
Cantor Fitzgerald
Hold
Maintained
$350.00
-0.4%
04/30/2026
Tazeen Ahmad
Bank of America Securities
Sell
Reiterated
$307.00
-12.6%
05/01/2026
Unknown Analyst
J.P. Morgan
Hold
Initiated
$300.00
-14.6%
05/01/2026
Gregory Renza
Truist Financial
Hold
Maintained
$327.00
-6.9%
05/01/2026
Geoff Meacham
Citi
Hold
Maintained
$345.00
-1.8%
05/01/2026
Louise Chen
Scotiabank
Buy
Maintained
$385.00
+9.6%
05/01/2026
Gary Nachman
Canaccord Genuity
Hold
Maintained
$366.00
+4.2%
05/01/2026
Unknown Analyst
Canaccord Genuity
Hold
Initiated
$366.00
+4.2%
04/21/2026
Michael Yee
UBS
Buy
Maintained
$400.00
+13.8%
04/13/2026
Mohit Bansal
Wells Fargo
Hold
Reiterated
$390.00
+11%
04/02/2026
Akash Tewari
Jefferies
Hold
Initiated
$350.00
-0.4%
03/10/2026
Unknown Analyst
Argus Research
Buy
Maintained
$400.00
+13.8%
02/06/2026
Jay Olson
Oppenheimer
Buy
Maintained
$400.00
+13.8%
01/29/2026
Last report
Apr 30, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$5.15 / $4.77
+8.04%beat
Revenue / Est. (USD)
8.62B / 8.57B
+0.55%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
9.18B
9.56B
9.87B
8.62B
Cost of goods sold
2.67B
2.74B
2.68B
2.50B
Cost of revenue
2.67B
2.74B
2.68B
2.50B
Research and development expenses
1.74B
1.90B
2.14B
1.72B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.69B
1.72B
1.95B
1.60B
Operating expense
3.50B
3.55B
4.18B
3.21B
Total operating expenses
6.18B
6.29B
6.85B
5.70B
Operating income
3.00B
3.26B
3.01B
2.91B
Other non operating income
-113.00M
181.00M
143.00M
192.00M
EBT including unusual items
1.57B
3.92B
1.51B
2.08B
EBT excluding unusual items
2.37B
2.72B
2.51B
2.37B
Income tax expense
136.00M
705.00M
181.00M
265.00M
Effective tax rate
8.67%
17.98%
11.96%
12.72%
Other operating expenses
68.00M
-71.00M
82.00M
-113.00M
Net income
1.43B
3.22B
1.33B
1.82B
Net profit margin
15.60%
33.65%
13.51%
21.11%
Earnings per share
6.02
5.64
5.29
5.15
Interest and investment income
-
-
408.00M
-
Interest expense
-694.00M
-685.00M
-1.06B
-657.00M
Net interest expenses
-694.00M
-685.00M
-653.00M
-657.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.34B
4.57B
4.02B
4.03B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer